These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21037125)

  • 1. Efficiency of venlafaxine in patients with psychogenic nonepileptic seizures and anxiety and/or depressive disorders.
    Pintor L; Baillés E; Matrai S; Carreño M; Donaire A; Boget T; Setoain X; Rumia J; Bargalló N
    J Neuropsychiatry Clin Neurosci; 2010; 22(4):401-8. PubMed ID: 21037125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venlafaxine extended-release in patients older than 80 years with depressive syndrome.
    Baca E; Roca M; Garcia-Calvo C; Prieto R
    Int J Geriatr Psychiatry; 2006 Apr; 21(4):337-43. PubMed ID: 16570327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response.
    Perugi G; Frare F; Toni C; Ruffolo G; Torti C
    Neuropsychobiology; 2002; 46(3):145-9. PubMed ID: 12422062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study.
    Amsterdam JD; Shults J
    J Clin Psychopharmacol; 2008 Apr; 28(2):171-81. PubMed ID: 18344727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety.
    De Nayer A; Geerts S; Ruelens L; Schittecatte M; De Bleeker E; Van Eeckhoutte I; Evrard JL; Linkowski P; Fossion P; Leyman S; Mignon A
    Int J Neuropsychopharmacol; 2002 Jun; 5(2):115-20. PubMed ID: 12135535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis of the effects of venlafaxine on anxiety associated with depression.
    Rudolph RL; Entsuah R; Chitra R
    J Clin Psychopharmacol; 1998 Apr; 18(2):136-44. PubMed ID: 9555599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
    Sheehan DV
    J Clin Psychiatry; 2001; 62 Suppl 19():26-31. PubMed ID: 11577788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder.
    Sheehan DV
    J Clin Psychiatry; 1999; 60 Suppl 22():23-8. PubMed ID: 10634352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open clinical trial of venlafaxine treatment of fibromyalgia.
    Dwight MM; Arnold LM; O'Brien H; Metzger R; Morris-Park E; Keck PE
    Psychosomatics; 1998; 39(1):14-7. PubMed ID: 9538670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care.
    Lenox-Smith AJ; Reynolds A
    Br J Gen Pract; 2003 Oct; 53(495):772-7. PubMed ID: 14601352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression.
    Ladd CO; Newport DJ; Ragan KA; Loughhead A; Stowe ZN
    Depress Anxiety; 2005; 22(2):94-7. PubMed ID: 16094663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive behavioral therapy for psychogenic nonepileptic seizures.
    LaFrance WC; Miller IW; Ryan CE; Blum AS; Solomon DA; Kelley JE; Keitner GI
    Epilepsy Behav; 2009 Apr; 14(4):591-6. PubMed ID: 19233313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lithium augmentation of venlafaxine: an open-label trial.
    Hoencamp E; Haffmans J; Dijken WA; Huijbrechts IP
    J Clin Psychopharmacol; 2000 Oct; 20(5):538-43. PubMed ID: 11001238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression.
    Malhi GS; Ng F; Berk M
    Aust N Z J Psychiatry; 2008 Apr; 42(4):346-9. PubMed ID: 18330778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combined treatment of venlafaxine and quetiapine for treatment-resistant depression: a clinical study.
    Li X; Xing B; Yu E; Chen W; Wu H
    J Neuropsychiatry Clin Neurosci; 2013; 25(2):157-60. PubMed ID: 23686035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venlafaxine XR in the treatment of anxiety.
    Hackett D
    Acta Psychiatr Scand Suppl; 2000; (406):30-5. PubMed ID: 11131468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients.
    Diaz-Martinez A; Benassinni O; Ontiveros A; Gonzalez S; Salin R; Basquedano G; Martinez RA
    Clin Ther; 1998; 20(3):467-76. PubMed ID: 9663362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE; Franznick DA; Hollander SB; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of high dose of venlafaxine XL in treatment resistant major depression.
    Mbaya P
    Hum Psychopharmacol; 2002 Oct; 17(7):335-9. PubMed ID: 12415551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression.
    Hsiao CC
    Psychoneuroendocrinology; 2006 Aug; 31(7):839-46. PubMed ID: 16716529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.